SecBot SecBot
PRESS-RELEASE ·Filed Oct 26, 2026

EIKN

Eikon Therapeutics, Inc.
BULLISH
Impact 6/10
Processed1h 29m ago Wirepress-3387904
Press release · FDA

Price Chart

Loading chart...

Investment Themes

Biotech & Drug Discovery

Documents Analyzed

This report is based on 1 press release from GlobeNewswire.

DocumentAccession Number
PRESS-RELEASE Data (Synthetic)press-3387904
13 reports for EIKN
Performance horizon

Track record builds as more directional reports settle.

Filters
Rows
Reports for EIKN — sortable, filterable
TypeNow
Oct 26, 2026
today
8-K
NEUTRAL ★ 5/10
$7.48awaiting T+20—$7.26 (−2.94%)
Oct 26, 2026
today
Press Release
BULLISH ★ 6/10
$7.48awaiting T+20—$7.26 (−2.94%)
Oct 23, 2026
2d ago
8-K
NEUTRAL ★ 4/10
$8.01awaiting T+20—$7.26 (−9.36%)
Oct 7, 2026
18d ago
SC 13G/A
NEUTRAL ★ 3/10
$7.54awaiting T+20—$7.26 (−3.71%)
Oct 2, 2026
23d ago
SC 13G/A
NEUTRAL ★ 3/10
$7.33awaiting T+20—$7.26 (−0.95%)
Sep 22, 2026
4w ago
Institutional Cluster
NEUTRAL ★ 3/10
$8.98 $8.18▼ −8.91%▼ −8.35%$7.26 (−19.15%)
Sep 8, 2026
6w ago
Insider Buy
BULLISH ★ 5/10
$10.73 $7.54▼ −29.73%▼ −31.67%$7.26 (−32.34%)
Sep 3, 2026
7w ago
Press Release
NEUTRAL ★ 3/10
$10.96 $8.04▼ −26.64%▼ −25.52%$7.26 (−33.76%)
Aug 13, 2026
10w ago
8-K
NEUTRAL ★ 3/10
$11.05awaiting T+20—$7.26 (−34.30%)
Jul 20, 2026
13w ago
Press Release
NEUTRAL ★ 3/10
$9.65 $10.47▲ +8.50%▲ +4.38%$7.26 (−24.77%)
Showing 10 of 13

US Market Status

Market Closed — Opens in 1h 59m

Subscribe to SecBot

Get Real-Time SEC Filing Intelligence

Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.

Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers
Report published Oct 26, 2026

Fresh EIKN Intelligence

Analysis is for subscribers only.

Eikon Therapeutics presented updated Phase 2 data for its TLR7/8 agonist EIK1001 in first-line stage 4 NSCLC at ESMO 2026. The squamous cohort showed a 72.4% ORR and 100% DCR with median DOR of 12.9 months; the non-squamous cohort showed 55.6% ORR and 80.6% DCR.

Subscribe for Full Access